e.l.f. Beauty (ELF) plunges as tariff hit and soft FY‑2026 outlook overshadow Rhode boost: what to know today (Nov. 6, 2025)

6 November 2025

Shares slid more than 20% after e.l.f. set a FY‑2026 revenue outlook of $1.55–$1.57B and adjusted EPS of $2.80–$2.85, both below Street expectations; after‑hours losses reached ~26%. ^[1]
Tariff costs >$50M expected this year and a heavy China sourcing mix (~75%) are pressuring gross margin (69%, –165 bps). ^[2]
Q2 FY‑2026 (quarter ended Sept. 30): net sales up 14% to $343.9M; adjusted EPS $0.68; Rhode’s Sephora debut was “record‑breaking,” helping share gains of +140 bps for the e.l.f. brand. ^[3]

What happened

e.l.f. Beauty’s stock is tumbling today after the company’s fiscal Q2 print and FY‑2026 guidance underwhelmed investors. In last night’s release, management guided to $1.55–$1.57 billion in sales and $2.80–$2.85 adjusted EPS for FY‑2026, short of consensus (~$1.65B and ~$3.58). The outlook reflects a step‑down in profitability as U.S. import tariffs lift costs and growth in the core e.l.f. brand moderates versus last year’s blockbuster product cycle. Shares fell as much as ~26% after hours Wednesday and were still sharply lower in early Thursday trading. ^[4]

By the numbers (Q2 FY‑2026)

Net sales:$343.9M (+14% YoY).
Gross margin:69% (–165 bps YoY), with the decline primarily from higher tariff costs.
Adjusted EPS:$0.68; GAAP EPS:$0.05.
Adjusted EBITDA:$66.2M (19% margin).
Brand momentum: The quarter included +140 bps of market‑share gains for e.l.f. and a record‑breaking launch of Rhode at Sephora North America.
Six‑month (YTD) sales:$697.7M (+12% YoY).
Balance sheet (9/30/25):$194.4M cash; $831.6M long‑term debt. ^[5]

Guidance snapshot vs. last year

FY‑2026 sales:$1.55–$1.57B (vs. $1.314B in FY‑2025 actuals).
Adjusted EPS:$2.80–$2.85 (vs. $3.39 FY‑2025).
Adjusted EBITDA:$302–$306M (vs. $297M FY‑2025). ^[6]

Why the sell‑off is so steep

Two pressure points stand out:

Tariffs and sourcing mix. e.l.f. expects more than $50 million of tariff costs in FY‑2026; about 75% of products are made in China, magnifying the impact on margins. Management also said it does not plan further price increases after August’s $1 list‑price action. ^[7]
Core brand deceleration. Commentary around softer innovation versus last year’s hit lip launches, and greater reliance on newly acquired Rhode, tempered near‑term growth expectations in the mature e.l.f. franchise. ^[8]

Wall Street reaction today

Piper Sandler cut the stock to Neutral from Overweight and slashed its target to $100 citing slower implied core growth and a profitability reset. ^[9]
UBSreduced its target to $105 (Neutral), highlighting valuation and the softer guide. ^[10]
TD Cowentrimmed its target to $110 following the report. ^[11]

Rhode’s role—helpful, but not a cure‑all (yet)

Rhode’s early performance is a bright spot—a “record‑breaking” Sephora North America launch with further U.K. rollout slated for Nov. 10—and is expected to be a meaningful contributor this year. Still, even with Rhode’s momentum, the Street is recalibrating given margin headwinds and a lower EPS baseline. ^[12]

What to watch next

Tariff strategy & supply chain diversification. Any concrete shift away from China or tariff relief could be a key catalyst for margins. ^[13]
Holiday sell‑through and newness cadence. Q4 merchandising (value gift sets, lip/eye franchises) will be scrutinized to gauge whether core demand re‑accelerates. (Context via company and trade coverage.) ^[14]
Analyst revisions and rating drift. After today’s downgrades and target cuts, watch if other brokers follow. ^[15]

Editor’s note & methodology

Figures for the quarter and full‑year outlook come directly from e.l.f. Beauty’s Nov. 5, 2025 press release. After‑hours move, tariff magnitude, and sourcing mix are corroborated by independent reporting. Analyst actions are sourced from broker‑note roundups and wire services published this morning. All data are as of Nov. 6, 2025.

This article is for informational purposes only and is not investment advice.

e.l.f. Beauty shares plummet as guidance lower-than-expected on tariff worries

Watch this video on YouTube.

References

1. www.reuters.com, 2. www.reuters.com, 3. investor.elfbeauty.com, 4. investor.elfbeauty.com, 5. investor.elfbeauty.com, 6. investor.elfbeauty.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.tipranks.com, 10. www.investing.com, 11. www.streetinsider.com, 12. investor.elfbeauty.com, 13. www.reuters.com, 14. investor.elfbeauty.com, 15. www.tipranks.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Bitcoin $68K Too Low vs Gold, JPMorgan Says as BTC and Stocks Slip
November 6, 2025, 4:58 PM EST. Bitcoin joined US stocks in pulling back as macro data fueled risk-aversion. BTC/USD hovered near the $102,000 level while the S&P 500 and Nasdaq drifted lower on job-cut news and rising US household debt. Challenger, Gray & Christmas reported more than 153,000 layoffs in October, underscoring cautious sentiment ahead of the Fed's likely policy pivot. Traders see odds of a December 0.25% cut around 69%, though some warn policymakers may pause as hawkish signals fade. JPMorgan's analysts argue BTC is now undervalued against gold, saying Bitcoin is about $68,000 too low, a line that could renew upside if ETF outflows stabilize. CME futures gap near $92k remains a psychological target as risk assets await clearer macro cues.
Morning Bid: Wall Street Gets Vertigo as Tech Selloff Spreads
November 6, 2025, 4:56 PM EST. Morning Bid: Wall Street trembles as a rare shakeout in Big Tech and chip stocks spills through global markets. The S&P 500 and Nasdaq slid more than 1% as investors fret over lofty valuations, even as Democrats fared well in local elections and Trump tariff hearings begin. Palantir's earnings miss and a bearish bet from Michael Burry underscore downside risk, while Nvidia and AMD moves drew attention after hours. Super Micro Computer tumbled on results, and Qualcomm and Costco loom on the docket. Traders eye ADP payrolls, the Fed, and the dollar as risk appetite remains fragile: Bitcoin briefly breached $100,000, and China data-center guidance nudges domestic production higher.
Salesforce Stock Target Prices: Mean Target $330.65, Street-High $430
November 6, 2025, 4:49 PM EST. CRM's market cap is about $242.2B, and the stock has lagged the market, down 24.4% YTD and 15.1% over the past 52 weeks. Despite a better-than-expected Q2 2026 EPS of $2.91 and revenue of $10.2B, Salesforce issued a cautious Q3 guide as AI investments like Agentforce weigh on near-term growth. Across ~50 analysts, the consensus rating is a Moderate Buy, with a mean price target of $330.65 (about 30.9% above current levels) and a street-high of $430 (roughly 70.2% upside). Mizuho's Gregg Moskowitz reaffirmed a Buy with a $350 target. The figures imply potential upside despite a softer near term, as investors weigh longer-term AI-driven expansion against macro headwinds.
HireQuest (HQI) Shareholders Endure 39% Loss Over Three Years as EPS Falls
November 6, 2025, 4:46 PM EST. Over the last three years, HireQuest (HQI) has underperformed the market: the stock is down about 42% vs a roughly 90% market gain, and it fell 41% in the past year. The company's EPS declined at about 38% per year, far outpacing the roughly 16% annual drop in the share price, suggesting sentiment may not fully reflect the earnings slide. The stock trades at a lofty P/E around 45.6, while the TSR over three years is about -39% (dividends boosted returns). Year-to-date, holders are down ~ 40% including dividends, versus the market up ~ 16%. Long-term, ~2% annualized gains over five years hint at potential value if fundamentals prove sustainable.
CTS (CTS) Fair-Value Check After 12% Three-Month Rally
November 6, 2025, 4:42 PM EST. CTS has climbed about 12% over the last three months, supported by steady year-over-year growth in revenue and net income. The near-term momentum keeps the stock on investors' radar, though the trailing 12-month total return remains negative. The latest narrative places CTS near its fair value, with a close at $43.26 suggesting the market and analyst expectations are aligned. The company's push into high-growth segments-medical (therapeutic and portable ultrasound) and industrial (EV charging, automation, connectivity)-could sustain revenue growth and improve margins, even as long-term headwinds persist in transportation and global trade tensions. A DCF view shows CTS trading roughly 0.7% below fair value, indicating a minor undervaluation that may or may not justify further exposure.